secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2022-04-26T23:59:59+00:00
Accession:  0001099800-22-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q1 sales $1.34B (+13% underlying), adjusted EPS $0.60; TAVR up 14% underlying
--------------------------------------------------------------------------------

- Q1 sales $1.34B, up 10% reported (13% underlying); adjusted EPS $0.60.
- TAVR sales $881M (+11% reported, +14% underlying); global TAVR opportunity seen doubling to $10B by 2028.
- Full-year 2022 guidance: sales $5.5-6.0B, adjusted EPS $2.50-$2.65; Q2 sales $1.36-1.44B.
- MITRIS RESILIA valve for mitral position received US FDA approval and launched commercially.
- Repurchased ~$400M stock in Q1; free cash flow $221M; cash $1.5B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980022000007/0001099800-22-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980022000007/ew-20220426.htm
  HTML page:      https://secwatch.observer/filing/0001099800-22-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer